Supplementary Materials

This PDF file includes:

  • Fig. S1. ENT treatment of aRMS in vivo.
  • Fig. S2. ENT reduces PAX3:FOXO1 abundance at a clinically relevant dose and time of exposure and reduces cell viability synergistically with VCR.
  • Fig. S3. PAX3:FOXO1 mRNA expression is reduced by ENT in aRMS cell lines.
  • Fig. S4. Better than other HDACis, ENT reduces PAX3:FOXO1 abundance in murine and human aRMS cells.
  • Fig. S5. Representative histology of PDX mouse aRMS tissue.
  • Fig. S6. PFI-3–mediated inhibition of SMARCA4 bromodomain activity.
  • Fig. S7. Validation of commercially available antibodies for detecting endogenous FOXO1 abundance in aRMS cell lines.
  • Table S1. Histological markers of differentiation in aRMS orthotopic allograft PDX mice.
  • Table S2. Treatment schedules for the CF-4/PCB-513 PDX mice.
  • Table S3. Patient history of the Champions Oncology PDX aRMS models.
  • Table S4. Patient history of The Jackson Laboratory PDX aRMS models.
  • Table S5. Histological scoring of markers of differentiation in PDX aRMS mice.
  • Table S6. Statistical analysis of CTG-1604/POS-14175 data.
  • Table S7. Statistical analysis of J101220/CF-4 data.
  • Table S8. Statistical analysis of J77636/PCB-481 data.
  • Table S9. Statistical analysis of J0103366/CF-13A data.
  • Table S10. Statistical analysis of J099761/CF-1 data.
  • Table S11. Statistical analysis of CTG-1409/POS 14107 data.
  • Table S12. Statistical analysis of J099873/CF-2 data.
  • Table S13. Statistical analysis of CTG-1008 data.

[Download PDF]